Histopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial.
Options
BORIS DOI
Publisher DOI
PubMed ID
41653087
Description
Background
The ACCURE trial demonstrated that appendicectomy reduces relapse rates within 1 year in patients with ulcerative colitis (UC) in remission. We aimed to explore appendiceal histopathology in quiescent UC and assess its association with postoperative relapse.Methods
Appendix specimens from Dutch participants in the ACCURE trial were reassessed by a blinded gastrointestinal pathologist using the Robarts Histopathology Index (RHI; range 0-33). Active appendiceal inflammation was defined as RHI > 3. Clinical data, preoperative endoscopic findings including peri-appendiceal red patch (PARP), and outcomes were correlated with histopathological findings. Inter-observer agreement between local and central scoring was assessed, along with relapse-free survival in relation to RHI severity.Results
Of 65 patients, 49 (75.4%) maintained remission and 16 (24.6%) relapsed within one year. Active inflammation was present in 55.4% (36/65). Inter-observer agreement was moderate (κ = 0.47, 95% CI 0.29-0.64, p < 0.001). Inflammation was more frequent in patients diagnosed at a younger age (median 28 vs. 34 years, p = 0.09), and greater in those with PARP (RHI 15.5 vs. 5.0, p = 0.005). Extensive epithelial neutrophil involvement (> 5% of crypts) was associated with higher relapse rates (44.4% vs. 18.0%, p = 0.05). Relapsing patients also had larger appendiceal diameters (median 9 vs. 7 mm, p = 0.03).Conclusion
Active appendiceal inflammation is prevalent in quiescent UC and showed a trend toward association with relapse risk. Although the benefit of appendicectomy in this group cannot be confirmed on these data alone, the finding might be clinically relevant as relapse rates are significantly reduced in the appendicectomy group.
The ACCURE trial demonstrated that appendicectomy reduces relapse rates within 1 year in patients with ulcerative colitis (UC) in remission. We aimed to explore appendiceal histopathology in quiescent UC and assess its association with postoperative relapse.Methods
Appendix specimens from Dutch participants in the ACCURE trial were reassessed by a blinded gastrointestinal pathologist using the Robarts Histopathology Index (RHI; range 0-33). Active appendiceal inflammation was defined as RHI > 3. Clinical data, preoperative endoscopic findings including peri-appendiceal red patch (PARP), and outcomes were correlated with histopathological findings. Inter-observer agreement between local and central scoring was assessed, along with relapse-free survival in relation to RHI severity.Results
Of 65 patients, 49 (75.4%) maintained remission and 16 (24.6%) relapsed within one year. Active inflammation was present in 55.4% (36/65). Inter-observer agreement was moderate (κ = 0.47, 95% CI 0.29-0.64, p < 0.001). Inflammation was more frequent in patients diagnosed at a younger age (median 28 vs. 34 years, p = 0.09), and greater in those with PARP (RHI 15.5 vs. 5.0, p = 0.005). Extensive epithelial neutrophil involvement (> 5% of crypts) was associated with higher relapse rates (44.4% vs. 18.0%, p = 0.05). Relapsing patients also had larger appendiceal diameters (median 9 vs. 7 mm, p = 0.03).Conclusion
Active appendiceal inflammation is prevalent in quiescent UC and showed a trend toward association with relapse risk. Although the benefit of appendicectomy in this group cannot be confirmed on these data alone, the finding might be clinically relevant as relapse rates are significantly reduced in the appendicectomy group.
Date of Publication
2026-02
Publication Type
Article
Subject(s)
Language(s)
en
Contributor(s)
Visser, Eva | |
Danielsson, Demy | |
Heuthorst, Lianne | |
D'Haens, Geert R | |
Bemelman, Willem A | |
Buskens, Christianne J |
Additional Credits
Series
United European Gastroenterology Journal
Publisher
Wiley
ISSN
2050-6414
2050-6406
Access(Rights)
open.access